1. Market Research
  2. > Pharmaceutical
  3. > Drug Delivery Market Trends
  4. > Microneedles for Transdermal and Intradermal Drug Delivery, 2014-2030

Microneedles for Transdermal and Intradermal Drug Delivery, 2014-2030

  • October 2014
  • -
  • Roots Analysis Private Ltd.
  • -
  • 210 pages

INTRODUCTION
Transdermal delivery via microneedles is increasingly gaining traction as one of the more promising drug delivery technologies. Microneedles are of a few hundred microns in size, capable of creating transient pores across the skin by penetrating the stratum corneum layer to deliver molecules. These needles are not big enough to reach the nerve-rich regions of the skin; as a result, the drug delivery is perceived as completely painless and devoid of bleeding. Drugs, vaccines, proteins, peptides and other biomolecules are suitable for delivery using the microneedle technology.

The market is still in its infancy. So far, only one microneedle based delivery device, Soluvia prefilled microinjection system, has reached the market. The vaccine-device combination product was FDA approved in May 2011 for intradermal delivery of Fluzone influenza vaccine. We have identified more than 25 companies, with proprietary microneedle technology, actively working towards the development of microneedle-based drug or vaccine products. Clearside Biomedical, NanoPass Technologies, Corium International, Circassia, Radius Health and Zosano Pharma are examples of companies which are evaluating microneedle based drug/vaccine – device combination products (referred to as products hereafter) in clinical trials.

During the course of our research, we came across 22 products currently in different stages of development. We expect around ten products to be launched by the end of this decade, providing the much needed push to this market. Technological advancements will ensure the development of microneedle systems with improved safety and efficacy profile. As more products move from pipeline to the market, we expect to see an increase in the investment in this area from various quarters.

SCOPE OF THE REPORT
The ‘Microneedles for Transdermal and Intradermal Drug Delivery, 2014-2030’ report provides an extensive study in the field of microneedle based delivery systems for therapeutic use. The report covers various aspects, such as, benefits of microneedle assisted drug delivery over conventional needle-syringe system, key industry stakeholders, manufacturing challenges and upcoming opportunities.

One of the key objectives of this report is to understand the current and future state of the microneedles market. This is done by analysing
- Products currently available in the market and those under development (both clinical / pre-clinical)
- Recent partnerships which have taken place over the last few years covering product co-development and technology licensing
- Spin-off companies from academic institutions carrying forward the research work to develop end-user products
- Competitive landscape and inherent threats to growth in the short and long term
- Development and sales potential based on target consumer segments, likely adoption rate and expected pricing

The base year for the report is 2013. The study provides short-mid term and long term market forecasts for the period 2014 - 2022 and 2022 - 2030, respectively. The research, analysis and insights presented in this report include potential sales of microneedle based delivery devices based on the adoption of 13 marketed and pipeline products; this analysis is backed by a deep understanding of key drivers behind the growth.

Owing to niche nature of the market, with most products in the pipeline, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.

For the scope of our report, we have only considered the microneedle products intended for medicinal use and excluded the microneedle-based products which are directed towards cosmetic applications. All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS
1. Microneedles can deliver a plethora of drugs and vaccines; the technology is not limited to any specific class of drugs. More than 70% of the products in development are patches incorporating solid or dissolvable needles, rest are hollow microneedle arrays which employ the use of a syringe.
2. About 12 products based on microneedle technology are currently in clinical development, more than half of which are in phase II or a higher stage of development. In addition, there are a number of other products currently in preclinical trials.
3. Amongst the various firms involved in developing microneedle products, almost 50% are start-ups, which have received financial support from various investors.
4. Many academic institutions are also exploring the use of microneedles for diagnostics, gene delivery and continuous drug monitoring purposes. Majority of these research projects are focused in developing microneedle products as easy-to-use wearable patches.
5. With several new microneedle based therapeutic product launches by the end of this decade, we expect the overall market for microneedle based delivery devices to reach annual sales of 485 million units by 2030.

RESEARCH METHODOLOGY
Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Other analysts’ opinion reports

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 presents an executive summary of the report. It offers a high level view on where the microneedles market is headed in the mid-long term.

Chapter 3 provides a general introduction to microneedles for transdermal drug delivery. In this section we have discussed, in detail, the concept of microneedles, their historical evolution, mechanism of action and advantages over traditional needle syringes.

Chapter 4 provides an overview of the market landscape. This chapter includes comprehensive information on various technology providers, types of microneedle products, associated materials and manufacturing processes. Information regarding the partnerships that have taken place in the past few years has also been included in this chapter.

Chapter 5 focuses on the key technology providers which have proprietary microneedle technology, with special reference to companies which have microneedle based products under clinical stage of development. In addition to providing detailed profiles of five leading players in the industry, we have also looked at 13 other players which are currently focused in this market.

Chapter 6 discusses the notable microneedle based research work currently underway in academia. It includes comprehensive information on various universities, along with their projects, which have taken a keen interest in this emerging research area.

Chapter 7 provides insights on all the products that are currently marketed or being developed based on the microneedle technology. All these drugs / vaccines have been profiled in this chapter. Amongst other things, these profiles include information related to drug specifications, current stage of development, clinical trials details etc.

Chapter 8 includes case studies of two additional products that are based on microneedle technology but employ a different mode of administration. In addition, we have also profiled a contract manufacturer which manufactures microneedle using its proprietary micro molding technology.

Chapter 9 identifies the forecasted future opportunity presented by the microneedle market. It includes our sales estimates on individual products that are currently marketed or are likely to be available in the near future. We have provided three different growth scenarios for the time period 2014 - 2030.

Chapter 10 provides our analysis of the strengths, weaknesses, opportunities and threats influencing the overall market, capturing the key elements likely to determine future growth.

Chapter 11 is a collection of interview transcripts; these discussions have helped us in forming a better understanding of the key market dynamics, competitive landscape and the likely future trends.

Chapter 12 summarises the overall report. In this chapter, we have provided a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures presented in the report.

Chapter 14 is an appendix, which lists down all the companies and organisations referenced in the report.

Table Of Contents

Microneedles for Transdermal and Intradermal Drug Delivery, 2014-2030
TABLE OF CONTENTS
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION TO MICRONEEDLES
3.1. What are Microneedles?
3.2. Historical Evolution
3.3. Why Transdermal Mode of Drug Administration?
3.4. The Need for Using Microneedles
3.5. Drawbacks of Conventional Needle Based Delivery
3.6. Benefits of Microneedle Based Delivery System
3.7. Types of Microneedles
3.7.1. Solid Microneedles
3.7.2. Hollow Microneedles
3.7.3. Dissolvable Microneedles

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Transdermal Drug Delivery Systems
4.3. Manufacturing
4.3.1. MEMS Technology
4.3.2. Micromilling Technology
4.4. Microneedle Technology Providers
4.5. Recent Partnerships

5. TECHNOLOGY PROVIDERS
5.1. Chapter Overview
5.2. Becton Dickinson (BD)
5.2.1. Soluvia: Prefillable Microinjection System
5.2.2. Marketing Approvals
5.2.3. Sales Performance
5.2.4. Partnerships

5.3. Clearside Biomedical
5.3.1. Microinjector
5.3.1.1. Patents
5.3.1.2. Manufacturing Capability
5.3.2. Product Pipeline
5.3.3. Funding
5.3.4. Partnership

5.4. Corium International
5.4.1. MicroCor Technology
5.4.1.1. Delivery Through an Applicator
5.4.1.2. Manufacturing Capability
5.4.2. Product Pipeline
5.4.3. Sales Performance
5.4.4. Partnership
5.4.5. Funding
5.4.6. Future Plans

5.5. NanoPass Technologies
5.5.1. MicronJet 600 Needle
5.5.1.1. US and EU Device Approval
5.5.1.2. Manufacturing Capabilities
5.5.2. Product Pipeline
5.5.3. Partnerships
5.5.4. Funding

5.6. Zosano Pharma
5.6.1. ZP Patch Technology
5.6.1.1. Applicator Device
5.6.2. Product Pipeline
5.6.3. Funding
5.6.4. Partnerships
5.6.5. Future Plans

5.7. Other Technology Providers
5.7.1. 3M Drug Delivery Systems
5.7.1.1. Microneedle Technology
5.7.1.2. Sales Performance
5.7.1.3. Partnerships

5.7.2. Apogee Technology
5.7.2.1. PyraDerm
5.7.2.2. Partnership

5.7.3. BioSerenTach Inc.
5.7.3.1. Dissolvable Microneedle (DM) Chip
5.7.3.2. Recent Developments

5.7.4. Debiotech
5.7.4.1. DebioJect System
5.7.4.2. Clinical Trials
5.7.4.3. Partnerships and Awards

5.7.5. FluGen
5.7.5.1. Technology
5.7.5.2. Funding

5.7.6. Fujifilm
5.7.6.1. Micro-Needle Array
5.7.6.2. Sales Performance

5.7.7. ImmuPatch
5.7.7.1. ImmuPatch Technology
5.7.7.2. Research and Funding

5.7.8. Micropoint Technologies
5.7.8.1. Microneedle Technology
5.7.8.2. Funding

5.7.9. nanoBioSciences
5.7.9.1. AdminPen Injection System

5.7.10. Nemaura Pharma
5.7.10.1. Microneedle Technology
5.7.10.2. Recent Developments

5.7.11. TheraJect
5.7.11.1. TheraJect MAT System
5.7.11.2. Research and Funding

5.7.12. Valeritas
5.7.12.1. Micro-Trans Microneedle System
5.7.12.2. Funding and Awards

5.7.13. Vaxxas
5.7.13.1. Nanopatch
5.7.13.2. Partnership and Funding

6. ACADEMIA
6.1. Chapter Overview
6.2. Queen's University Belfast
6.2.1. Microneedle Technology
6.2.2. Advantages
6.2.3. Awards and Opportunity

6.3. Emory and Georgia Technology
6.3.1. Microneedle Technology
6.3.2. Research Programs
6.3.3. Other Developments

6.4. North Carolina State University and University of California, San Diego
6.4.1. Research Programs

6.5. University of Pittsburgh
6.5.1. Research Programs

6.6. University of Washington
6.6.1. Research Programs

6.7. Cardiff University
6.7.1. Research Programs

7. PRODUCT PROFILES
7.1. Chapter Overview
7.2. Fluzone Intradermal, Sanofi Pasteur
7.2.1. Regulatory Approvals
7.2.2. Pricing
7.2.3. Manufacturing

7.3. Intanza, Sanofi Pasteur
7.3.1. Regulatory Approval
7.3.2. Manufacturing

7.4. Polio Vaccine, NanoPass Technologies
7.4.1. Increased use of IPV
7.4.2. Microneedle Assisted IPV
7.4.3. Clinical Trials

7.5. CLS-1001, Clearside Biomedical
7.5.1. Clinical Trials
7.5.2. Future Plans

7.6. Cat-SPIRE, Circassia
7.6.1. ToleroMune Technology
7.6.2. Partnership for Intradermal Delivery
7.6.3. Clinical Trials
7.6.4. Future Plans

7.7. Abaloparatide-TD (BA058), Radius Health
7.7.1. Clinical Trials
7.7.2. Manufacturing
7.7.3. Funding and Collaborations
7.7.4. Future Plans

7.8. CLS-1003, Clearside Biomedical
7.8.1. Future Plans

7.9. Ragweed-SPIRE, Circassia
7.9.1. Clinical Trials
7.9.2. Future Plans

7.10. Grass-SPIRE, Circassia
7.10.1. Clinical Trials
7.10.2. Future Plans

7.11. ZP-PTH Weekly, Zosano Pharma
7.11.1. Clinical Trials
7.11.2. Future Plans

7.12. MicroCor PTH, Corium International
7.12.1. Clinical Trials
7.12.2. Future Plans

7.13. HDM-SPIRE, Circassia
7.13.1. Clinical Trials
7.13.2. Future Plans

7.14. ZP-Glucagon, Zosano Pharma
7.14.1. Clinical Trials
7.14.2. Future Plans

7.15. H5N1 Avian Influenza VLP Vaccine, Medicago
7.15.1. VLP Technology
7.15.2. Intradermal Formulation
7.15.3. Clinical Trials

7.16. Products in Preclinical Trials

8. CASE STUDIES
8.1. Chapter Overview
8.2. Rapid Infuser and V-Go (Valeritas, Inc.)
8.2.1. Introduction
8.2.2. Rapid Infuser
8.2.2.1. Key Features
8.2.2.2. Advantages
8.2.3. V-Go
8.2.3.1. Key Features
8.2.3.2. Advantages

8.3. BD Libertasâ„¢ Patch Injector (BD Medical)
8.3.1. Introduction
8.3.2. Product Description
8.3.3. Usage / Mechanism
8.3.4. Advantages
8.3.5. Current Status

8.4. Phillips Medisize Corporation
8.4.1. Company Overview
8.4.2. Microneedle Based Drug Delivery
8.4.3. Microneedle Manufacturing

9. MARKET FORECAST, 2014-2030
9.1. Chapter Overview
9.2. Scope and Limitations
9.3. Forecast Methodology
9.4. Overall Microneedles Market for Drug Delivery, 2014-2030
9.5. Soluvia (Becton Dickinson)
9.5.1. Soluvia Sales forecast: Short-Mid Term, 2014-2022
9.5.2. Soluvia Sales forecast: Long Term, 2022-2030
9.6. Polio Vaccine (Nanopass Technologies)
9.6.1. Polio Vaccine Sales Forecast: Short-Mid Term, 2014-2022
9.6.2. Polio Vaccine Sales Forecast: Long Term, 2022-2030
9.7. CLS-1001 (Clearside Biomedical)
9.7.1. CLS-1001 Sales Forecast: Short-Mid Term, 2014-2022
9.7.2. CLS-1001 Sales Forecast: Long Term, 2022-2030
9.8. Cat-SPIRE (Circassia)
9.8.1. Cat-SPIRE Sales Forecast: Short-Mid Term, 2014-2022
9.8.2. Cat-SPIRE Sales Forecast: Long Term, 2022-2030
9.9. BA058 (Radius Health)
9.9.1. BA058 Sales Forecast: Short-Mid Term, 2014-2022
9.9.2. BA058 Sales Forecast: Long Term, 2022-2030
9.10. CLS-1003 (Clearside Biomedical)
9.10.1. CLS-1003 Sales Forecast: Short-Mid Term, 2014-2022
9.10.2. CLS-1003 Sales Forecast: Long Term, 2022-2030
9.11. Flu Vaccine Patch (Dr. Prausnitz Group)
9.11.1. Flu Vaccine Patch Sales Forecast: Short-Mid Term, 2014-2022
9.11.2. Flu Vaccine Patch Sales Forecast: Long Term, 2022-2030
9.12. Ragweed-SPIRE (Circassia)
9.12.1. Ragweed-SPIRE Sales Forecast: Short-Mid Term, 2014-2022
9.12.2. Ragweed-SPIRE Sales Forecast: Long Term, 2022-2030
9.13. Grass-SPIRE (Circassia)
9.13.1. Grass-SPIRE Sales Forecast: Short-Mid Term, 2014-2022
9.13.2. Grass-SPIRE Sales Forecast: Long Term, 2022-2030
9.14. ZP-PTH Weekly (Zosano Pharma)
9.14.1. ZP-PTH Weekly Sales Forecast: Short-Mid Term, 2014-2022
9.14.2. ZP-PTH Weekly Sales Forecast: Long Term, 2022-2030
9.15. MicroCor PTH (Corium International)
9.15.1. MicroCor PTH Sales Forecast: Short-Mid Term, 2014-2022
9.15.2. MicroCor PTH Sales Forecast: Long Term, 2022-2030
9.16. HDM-SPIRE (Circassia)
9.16.1. HDM-SPIRE Sales Forecast: Short-Mid Term, 2014-2022
9.16.2. HDM-SPIRE Sales Forecast: Long Term, 2022-2030
9.17. ZP-Glucagon (Zosano Pharma)
9.17.1. ZP-Glucagon Sales Forecast: Short-Mid Term, 2014-2022
9.17.2. ZP-Glucagon Sales Forecast: Long Term, 2022-2030

10. SWOT ANALYSIS
10.1. Strengths
10.2. Weakness
10.3. Opportunities
10.4. Threats

11. INTERVIEW TRANSCRIPTS
11.1. Interview 1: Nemaura Pharma, Dr. Faz Chowdhury, CEO
11.2. Interview 2: TheraJect, Dr. Sung Yun Kwon, CEO
11.3. Interview 3: North Carolina State University, Dr. Roger Narayan, Professor
11.4. Interview 4: Clearside Biomedical, Steve Lang, VP, Commercial Operations

12. CONCLUSION
12.1. Microneedles: Alternative to Hypodermic Injections
12.2. Academia is at the Forefront of Research; Spin-offs will Drive Commercial Applications
12.3. Emerging Market, with A Huge Growth Potential
12.4. Contract Manufacturers Likely to Play an Important Role in Realising the Ambition
12.5. Concluding Remarks

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS

LIST OF FIGURES

Figure 3.1 Viral Infection Cases Due to Unsafe Injections (in 000')
Figure 4.1 Transdermal Products: Distribution by Technology
Figure 4.2 Microneedle Devices: Distribution by Patches and Syringes
Figure 4.3 Microneedle Devices: Distribution by Type of Microneedle
Figure 5.1 BD: Sales, 2013-Q3, 2014 (USD Billion)
Figure 5.2 BD: 2013 Sales by Business Division (USD Billion)
Figure 5.3 BD Medical: 2013 Sales by Product Segment (USD Billion)
Figure 5.4 Corium: Sales Q2-Q3, 2014 (USD Million)
Figure 5.5 3M: Sales, 2009-2013 (USD Billion)
Figure 5.6 Fujifilm: Sales, 2014 (JPY Billion)
Figure 7.1 Distribution of Marketed / Pipeline Products using Microneedle Systems
Figure 9.1 Overall Microneedle Market for Drug Delivery (Million Units), 2014 - 2030
Figure 9.2 Soluvia Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.3 Soluvia Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
Figure 9.4 Polio Vaccine Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.5 Polio Vaccine Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
Figure 9.6 CLS-1001 Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.7 CLS-1001 Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
Figure 9.8 Cat-SPIRE Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.9 Cat-SPIRE Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
Figure 9.10 BA058 Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.11 BA058 Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
Figure 9.12 CLS-1003 Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.13 CLS-1003 Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
Figure 9.14 Flu Vaccine Patch Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.15 Flu Vaccine Patch Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
Figure 9.16 Ragweed-SPIRE Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.17 Ragweed-SPIRE Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
Figure 9.18 Grass-SPIRE Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.19 Grass-SPIRE Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
Figure 9.20 ZP-PTH Weekly Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.21 ZP-PTH Weekly Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
Figure 9.22 MicroCor PTH Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.23 MicroCor PTH Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
Figure 9.24 HDM-SPIRE Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.25 HDM-SPIRE Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
Figure 9.26 ZP-Glucagon Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.27 ZP-Glucagon Sales Forecast (Million Units): Long Term, 2022-2030(Base Scenario)
Figure 12.1 Overall Microneedles Market for Drug Delivery (Million Units): 2104, 2022 and 2030

LIST OF TABLES

Table 4.1 Approved Transdermal Drug Delivery Systems
Table 4.2 Top 30 MEMS Companies, 2012
Table 4.3 Microneedle Based Drug Delivery: Technology Providers
Table 4.4 Microneedle Based Drug Delivery: List of Partnerships
Table5.1 Other Companies Active in the Field of Microneedles
Table 5.2 Soluvia: Approvals
Table 5.3 Clearside Biomedical: Product Portfolio
Table 5.4 Corium: Product Portfolio
Table 5.5 NanoPass Technologies: Product Portfolio
Table 5.6 Zosano Pharma: Product Portfolio
Table 5.7 AdminPen Pricing
Table 5.8 AdminPatch Array Pricing
Table 6.1 University Research Technologies
Table 7.1 Marketed or Pipeline Drugs/Vaccines using Microneedle Systems
Table 9.1 Microneedle Based Products: Expected Launch Timelines
Table 10.1 SWOT Analysis
Table 13.1 BD: Sales, 2013-Q3, 2014 (USD Billion)
Table 13.2 BD: 2013 Sales by Business Division (USD Billion)
Table 13.3 BD Medical: 2013 Sales by Product Segments (USD Billion)
Table 13.4 Corium: Sales Q2-Q3, 2014 (USD Million)
Table 13.5 3M: Sales, 2009-2013 (USD Billion)
Table 13.6 Fujifilm: Sales, 2014 (JPY Billion)
Table 13.7 Overall Microneedle Market for Drug Delivery (Million Units), 2014-2030 (Base Scenario)
Table 13.8 Overall Microneedle Market for Drug Delivery (Million Units), 2014-2030 (Optimistic Scenario)
Table 13.9 Overall Microneedle Market for Drug Delivery (Million Units), 2014-2030 (Conservative Scenario)
Table 13.10 Soluvia Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.11 Soluvia Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.12 Soluvia Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.13 Soluvia Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.14 Soluvia Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.15 Soluvia Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
Table 13.16 Polio Vaccine Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.17 Polio Vaccine Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.18 Polio Vaccine Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.19 Polio Vaccine Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.20 Polio Vaccine Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.21 Polio Vaccine Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
Table 13.22 CLS-1001 Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.23 CLS-1001 Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.24 CLS-1001 Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.25 CLS-1001 Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.26 CLS-1001 Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.27 CLS-1001 Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
Table 13.28 Cat-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.29 Cat-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.30 Cat-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.31 Cat-SPIRE Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.32 Cat-SPIRE Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.33 Cat-SPIRE Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
Table 13.34 Abaloparatide-TD Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.35 Abaloparatide-TD Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.36 Abaloparatide-TD Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.37 Abaloparatide-TD Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.38 Abaloparatide-TD Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.39 Abaloparatide-TD Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
Table 13.40 CLS-1003 Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.41 CLS-1003 Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.42 CLS-1003 Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.43 CLS-1003 Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.44 CLS-1003 Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.45 CLS-1003 Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
Table 13.46 Flu Vaccine Patch Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.47 Flu Vaccine Patch Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.48 Flu Vaccine Patch Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.49 Flu Vaccine Patch Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.50 Flu Vaccine Patch Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.51 Flu Vaccine Patch Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
Table 13.52 Ragweed-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.53 Ragweed-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.54 Ragweed-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.55 Ragweed-SPIRE Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.56 Ragweed-SPIRE Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.57 Ragweed-SPIRE Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
Table 13.58 Grass-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.59 Grass-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.60 Grass-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.61 Grass-SPIRE Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.62 Grass-SPIRE Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.63 Grass-SPIRE Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
Table 13.64 ZP-PTH Weekly Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.65 ZP-PTH Weekly Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.66 ZP-PTH Weekly Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.67 ZP-PTH Weekly Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.68 ZP-PTH Weekly Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.69 ZP-PTH Weekly Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
Table 13.70 MicroCor-PTH Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.71 MicroCor-PTH Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.72 MicroCor-PTH Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.73 MicroCor-PTH Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.74 MicroCor-PTH Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.75 MicroCor-PTH Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
Table 13.76 HDM-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.77 HDM-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.78 HDM-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.79 HDM-SPIRE Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.80 HDM-SPIRE Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.81 HDM-SPIRE Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
Table 13.82 ZP-Glucagon Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.83 ZP-Glucagon Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.84 ZP-Glucagon Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.85 ZP-Glucagon Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.86 ZP-Glucagon Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.87 ZP-Glucagon Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)

The following companies have been mentioned in this report.

1. 10X Technology
2. 3M Drug Delivery Systems
3. 3M Unitek
4. 4P Therapeutics
5. AAC
6. Abingworth
7. Advanced Technology Ventures
8. Agate Medical Investments
9. AKM
10. AllTranz
11. Alza Corporation
12. Amspar B.V
13. Analog Devices
14. Angiomed
15. Aphelion Capital
16. Apogee Technology
17. Asahi Kasei Pharma Corporation (AKP)
18. AvagoTechnologies
19. Bausch and Lomb
20. BB Biotech Ventures
21. Becton Dickinson
22. Biacore
23. Biochemics
24. BioMed Ventures
25. BioSerenTach
26. Biotech Growth N.V
27. Bosch
28. Brandon Capital
29. Brookside Capital
30. Canon
31. Capital Royalty L.P
32. Carrera
33. CEA-LETI
34. Cerametal
35. CHL Medical Partners
36. Circassia
37. Clearside Biomedical
38. Corium International
39. Curasen
40. Debiotech
41. Denso
42. D-Partners
43. Elcam Medical
44. Enterprise Ireland
45. Essex Woodlands Health Ventures
46. Extraject Technologies
47. F2 Biosciences III, L.P.
48. Flir Systems
49. FluGen
50. Forma Medical
51. Fraunhofer Institute
52. Freescale Semiconductor
53. Fujifilm
54. GE Sensing
55. Georgia Research Alliance Venture Fund
56. GSK
57. Hatteras Venture Partners
58. HBM BioVentures
59. HBM Partners
60. HealthCare Ventures
61. Hewlett Packard
62. HLM Venture Partners
63. Honeywell
64. IBM
65. ImmuPatch
66. Infineon Technologies
67. Invensense
68. Ipsen Pharma
69. Iscar
70. Israel HealthCare Ventures (IHCV)
71. Janisys
72. Janssen Pharmaceuticals
73. Kaiser Permanente Ventures
74. Kenan Flagler Business School Private Equity Fund
75. Kionix
76. Knowles Electronics
77. Knox LLC
78. Lexmark
79. Lonza Group Ltd.
80. Macroflux Corporation
81. Measurement Specialities Inc.
82. Mecaplast
83. Medicago
84. Memsic
85. Mercatus Capital and GITP (Global Innovations and Technology Platform) Investments
86. Merck
87. Metalor Dental
88. MicroCreate B.V
89. Micropoint Technologies
90. Mountain Group Capital
91. MPM Capital
92. Murata
93. nanoBioSciences
94. Nanopass
95. Nemaura Pharma
96. New Enterprise Associates (NEA)
97. Nissha Printing Co. Ltd
98. Nomura Phase4 Ventures
99. Novartis
100. Novo Nordisk
101. Novosanis
102. Ofer Hi-Tech
103. Omron
104. OneVentures
105. ONSET Ventures
106. Oxford NanoDelivery
107. Panasonic
108. Par Pharmaceuticals
109. Philips Medisize
110. Phillips Plastic Corporation
111. Phonak AG
112. Pitango Venture Capital
113. PKA SoftTouch Corp
114. Procter and Gamble
115. Pro-micron
116. ProQuest Investments
117. Quantum Technology Partners
118. Radius Health
119. Robert Bosch
120. Rolex
121. RusanoMedInvest (RMI)
122. Sanofi Pasteur
123. Santen Inc.
124. Seco
125. Seiko Epson
126. Sensata
127. Sony
128. ST Microelectronics
129. Star Surgical
130. StrataGent Life Sciences
131. TechnoPhage
132. Teva Pharmaceuticals
133. Texas Instruments
134. TheraJect
135. TransDerm Inc.
136. Triquint
137. Tyco Electronics
138. Ulis
139. UTC Aerospace
140. Valeritas
141. Vaxxas
142. Welsh, Carson, Anderson and Stowe (WCAS)
143. WFD Ventures
144. Zosano Pharma

The following organisations have been mentioned in this report.

1. Cardiff University
2. Emory University
3. European Medicines Agency (EMA)
4. Food and Drug Administration (FDA)
5. Georgia Institute of Technology
6. Georgia Research Alliance
7. Health Canada
8. Imperial College, London
9. Infectious Disease Research Institute (IDRI)
10. Institute of Materials Research and Engineering
11. Juvenile Diabetes Research Foundation (JDRF)
12. Kyoto Pharmaceutical University
13. National Institutes of Health (NIH)
14. National Science Foundation
15. North Carolina State University
16. Oxford University
17. PATH
18. Queen's University Belfast
19. Royal Institute of Technology, Stockholm
20. Shanghai Institute of MateriaMedica (SIMM)
21. St. Jude Children's Research Hospital
22. Technology Strategy Board
23. Tyndall National Institute
24. University College Cork (UCC)
25. University of California
26. University of Melbourne
27. University of Pittsburgh
28. University of Queensland
29. University of Washington
30. University of Wisconsin, Madison
31. Vaccine and Immunotherapy Centre of the CentreHospitalierUniversitaireVaudois (CHUV)
32. Vaccine and Infectious Disease Organization (VIDO)
33. World Health Organization (WHO)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Transdermal Drug Delivery System - Global Market Outlook (2016-2022)

Transdermal Drug Delivery System - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • November 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Transdermal Drug Delivery System market is accounted for $16.32 billion in 2015 and is expected to reach $36.58 billion by 2022 growing at a CAGR of 12.2%. Rising ...

Transdermal Drug Delivery Market Analysis & Trends – Technology (Thermal, Iontophoresis, Electroporation, Ultrasound, Electric Current, Microporation, Mechanical Arrays, Radio Frequency), Application - Forecast to 2025

Transdermal Drug Delivery Market Analysis & Trends – Technology (Thermal, Iontophoresis, Electroporation, Ultrasound, Electric Current, Microporation, Mechanical Arrays, Radio Frequency), Application - Forecast to 2025

  • $ 4200
  • Industry report
  • November 2016
  • by Accuray Research LLP

The Global Transdermal Drug Delivery Market is poised to grow at a CAGR of around 11.6% over the next decade to reach approximately $95.57 billion by 2025. Some of the prominent trends that the market ...

Global Transdermal Drug Delivery Systems Market Report 2016

Global Transdermal Drug Delivery Systems Market Report 2016

  • $ 2850
  • Industry report
  • August 2016
  • by 9Dimen Research

2016 Global Transdermal Drug Delivery Systems Report is a professional and in-depth research report on the world's major regional market conditions of the Transdermal Drug Delivery Systems industry, focusing ...

Microneedle Diagnostics

May 2016 $ 3850

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.